Frequency Therapeutics Past Earnings Performance
Past criteria checks 0/6
Frequency Therapeutics's earnings have been declining at an average annual rate of -33.4%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been declining at an average rate of 25% per year.
Key information
-33.4%
Earnings growth rate
47.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -25.0% |
| Return on equity | -161.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
Jan 01
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Jan 19Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year
Aug 18Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
Jul 31Frequency Therapeutics (FREQ) Investor Presentation - Slideshow
Jun 18Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr 21Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be
Apr 04We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
Mar 15If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns
Jan 22Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?
Dec 27Frequency Therapeutics to host investor event in early January next year
Dec 18How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?
Dec 10Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 19Frequency Therapeutics EPS beats by $0.16, beats on revenue
Nov 16Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov 09Revenue & Expenses Breakdown
How Frequency Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -59 | 40 | -20 |
| 30 Jun 23 | 0 | -67 | 36 | 0 |
| 31 Mar 23 | 0 | -78 | 38 | 0 |
| 31 Dec 22 | 0 | -82 | 40 | 0 |
| 30 Sep 22 | 0 | -86 | 41 | 54 |
| 30 Jun 22 | 0 | -91 | 42 | 0 |
| 31 Mar 22 | 9 | -88 | 44 | 0 |
| 31 Dec 21 | 14 | -85 | 44 | 0 |
| 30 Sep 21 | 24 | -73 | 44 | 33 |
| 30 Jun 21 | 35 | -54 | 39 | 34 |
| 31 Mar 21 | 34 | -42 | 34 | 35 |
| 31 Dec 20 | 37 | -27 | 29 | 36 |
| 30 Sep 20 | 32 | -22 | 25 | 2 |
| 30 Jun 20 | 45 | -18 | 23 | 1 |
| 31 Mar 20 | 36 | -19 | 20 | 1 |
| 31 Dec 19 | 29 | -20 | 16 | 0 |
| 30 Sep 19 | 24 | -20 | 12 | -7 |
| 30 Jun 19 | 0 | -23 | 9 | 1 |
| 31 Mar 19 | 0 | -21 | 8 | 0 |
| 31 Dec 18 | 0 | -19 | 7 | 0 |
Quality Earnings: FREQ is currently unprofitable.
Growing Profit Margin: FREQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FREQ is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare FREQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FREQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: FREQ has a negative Return on Equity (-161.46%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/05 01:27 |
| End of Day Share Price | 2023/11/03 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Frequency Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Daniil Gataulin | Chardan Capital Markets, LLC |